Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An I-123-ADAM SPECT Imaging Study to Evaluate the Serotonin Transporter (SERT) Availability for Prognosing Major Depressive Disorder (MDD) Treatment and Assisting in Detecting MDD

NCT02473783 is registered in ClinicalTrials.gov with Tri-Service General Hospital (TSGH) as lead sponsor.

NCT NCT02473783
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02473783 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An I-123-ADAM SPECT Imaging Study to Evaluate the Serotonin Transporter (SERT) Availability for Prognosing Major Depressive Disorder (MDD) Treatment and Assisting in Detecting MDD
Lead sponsor
Tri-Service General Hospital (TSGH)
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2011
Completion date
November 30, 2012
Enrollment
37 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

major depressive disorder